Recombinant CX3CL1 (Quetmolimab Biosimilar) 抗体
This anti-CX3CL1 (Quetmolimab Biosimilar) antibody is a Humanized 单克隆 antibody detecting CX3CL1 (Quetmolimab Biosimilar) in ELISA, BLI, FACS, Func 和 SPR. Suitable for 人.
Quick Overview for Recombinant CX3CL1 (Quetmolimab Biosimilar) 抗体 (ABIN7581360)
抗原
CX3CL1 (Quetmolimab Biosimilar)
抗体类型
Recombinant Antibody
适用
人
宿主
Humanized
克隆类型
单克隆
标记
This CX3CL1 (Quetmolimab Biosimilar) antibody is un-conjugated
应用范围
ELISA, Bio-Layer Interferometry (BLI), Flow Cytometry (FACS), Functional Studies (Func), Surface Plasmon Resonance (SPR)
-
-
Expression System
- CHO Cells
-
原理
- Anti-CX3CL1 / Fractalkine Reference Antibody (quetmolimab)
-
序列
- QVQLVQSGAE VKKPGASVKV SCKASGYTFT NYYIHWVKQA PGQGLEWIGW IYPGDGSPKF NERFKGRTTL TADKSTNTAY MLLSSLRSED TAVYFCATGP TDGDYFDYWG QGTTVTVSSA STKGPSVFPL APCSRSTSES TAALGCLVKD YFPEPVTVSW NSGALTSGVH TFPAVLQSSG LYSLSSVVTV PSSNFGTQTY TCNVDHKPSN TKVDKTVERK CCVECPPCPA PPAAAPSVFL FPPKPKDTLM ISRTPEVTCV VVDVSHEDPE VQFNWYVDGV EVHNAKTKPR EEQFNSTFRV VSVLTVVHQD WLNGKEYKCK VSNKGLPAPI EKTISKTKGQ PREPQVYTLP PSREEMTKNQ VSLTCLVKGF YPSDIAVEWE SNGQPENNYK TTPPMLDSDG SFFLYSKLTV DKSRWQQGNV FSCSVMHEAL HNHYTQKSLS LSPGK,DIQMTQSPSS LSASVGDRVT ITCRASGNIH NFLAWYQQKP GKAPKLLIYN EKTLADGVPS RFSGSGSGTD YTLTISSLQP EDFATYFCQQ FWSTPYTFGG GTKVEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNNFY PREAKVQWKV DNALQSGNSQ ESVTEQDSKD STYSLSSTLT LSKADYEKHK VYACEVTHQG LSSPVTKSFN RGEC
-
产品特性
- Anti-CX3CL1 / Fractalkine Reference Antibody (quetmolimab) is expressed from CHO. The heavy chain type is huIgG2, and the light chain type is hukappa. It has a predicted MW of 145.5 kDa.
-
纯度
- >95 %
-
亚型
- IgG2SA
-
-
-
-
应用备注
- Optimal working dilution should be determined by the investigator.
-
说明
-
Therapeutic Agents by Target and Mechanism: CX3CL1 antagonist
-
限制
- 仅限研究用
-
-
-
状态
- Lyophilized
-
浓度
- 1 mg/mL
-
缓冲液
- 25 mM histidine, 8 % sucrose, 0.01 % Tween80 pH 6.2
-
储存条件
- 4 °C,-80 °C
-
储存方法
- +4°C,-80°C
-
-
- CX3CL1 (Quetmolimab Biosimilar)
-
物质类
- Biosimilar
-
分子量
- 145.5 kDa
-
UniProt
- P78423
抗原
-
You are here:
